WANY
RCKT icon

Wealthspire Advisors (New York)’s Rocket Pharmaceuticals RCKT Stock Holding History

Wealthspire Advisors (New York)’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20
Closed -$66 – 2449
2025
Q3 		$66 Buy
+20
New +$63 ﹤0.01% 3016

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wealthspire Advisors (New York)'s RCKT Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Rocket Pharmaceuticals (RCKT) in Q4 2025, closing a stake of 20 shares — an estimated $66 sold.

Wealthspire Advisors (New York) first reported a position in RCKT in Q3 2025 and held it in 1 quarter. The position peaked at $66 in Q3 2025. 186 funds tracked by Wall St. Rank hold RCKT as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Rocket Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 20 Rocket Pharmaceuticals shares in Q4 2025, an estimated $66.
  • Wealthspire Advisors (New York) first reported a position in Rocket Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Rocket Pharmaceuticals position peaked at $66 in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.